Health Canada Approves AbbVie's Skyrizi for Pediatric Plaque Psoriasis

AbbVie's Skyrizi (risankizumab) has been approved by Health Canada for pediatric patients aged 6 to under 18 with moderate-to-severe plaque psoriasis. This approval is based on the Phase III OptIMMize-1 study, which showed high rates of skin clearance. Skyrizi will be administered using a weight-based dosing regimen every 12 weeks after initial doses, expanding AbbVie's IL-23 inhibitor franchise in Canada.